Funding Opportunity RFA-DK-18-501 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN is composed of a Scientific and Data Coordination Center (SDCC) and Clinical Centers (CC). ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.

Funding Opportunity RFA-DK-18-502 from the NIH Guide for Grants and Contracts. The purpose of this funding opportunity announcement (FOA) is to continue the support the Childhood Liver Disease Research Network (ChiLDReN) to conduct clinical and translational research on rare pediatric liver diseases. ChiLDReN will be composed of a Scientific and Data Coordination Center (DCC), Clinical Centers (CC) , and the NIDDK/NIH as the sponsor of the Network. ChiLDReN will continue clinical and translational research on pediatric liver diseases that include: Biliary Atresia; Alagille syndrome; alpha-1-antitrypsin deficiency; Progressive Familial Intrahepatic Cholestasis syndromes; Bile acid synthesis defects; Mitochondrial hepatopathies; Idiopathic Neonatal Hepatitis; Cystic Fibrosis Liver Disease; and primary sclerosing cholangitis.

Funding Opportunity RFA-DA-19-014 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to develop and evaluate the loyalty/reward-based digital technologies (e.g., mobile medical app/device platforms and other digital technologies) to be used as a combination product to increase medication adherence. The objective of Phase I (R43) is to establish the feasibility and/or validation of the device, and Phase 2 is designed to test the efficacy of the reward-based platform in a larger sample. The primary endpoint is adherence to FDA-approved medications for substance use disorders. Rewards and contingencies should be delivered in a self-sustaining manner and include a front-end interface allowing treatment providers to monitor progress and deliver rewards. Platforms may include novel features including, but not limited to, automated tracking tools, real-time assessments of patient progress, medication intake, and momentary assessment. Data generated from these studies are to be used to support a 510k submission to seek clearance as an FDA cleared device.

Funding Opportunity RFA-DA-19-015 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is to develop and evaluate the loyalty/reward-based digital technologies (e.g., mobile medical app/device platforms and other digital technologies) to be used as a combination product to increase medication adherence. The objective of Phase I (R41) is to establish the feasibility and/or validation of the device, and Phase 2 is designed to test the efficacy of the reward-based platform in a larger sample. The primary endpoint is adherence to FDA-approved medications for substance use disorders. Rewards and contingencies should be delivered in a self-sustaining manner and include a front-end interface allowing treatment providers to monitor progress and deliver rewards. Platforms may include novel features including, but not limited to, automated tracking tools, real-time assessments of patient progress, medication intake, and momentary assessment. Data generated from these studies are to be used to support a 510k submission to seek clearance as an FDA cleared device.

Notice NOT-DA-18-038 from the NIH Guide for Grants and Contracts

Competitive Salary: EMBL: Bioinformatics Software Engineer and Data Manager Lo Germany (DE)

Funding Opportunity RFA-CA-19-002 from the NIH Guide for Grants and Contracts. The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments, and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.

Funding Opportunity PAR-18-924 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to seek research applications that pilot test approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care. Research applications should be developed to pilot test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal is that, if the pilot study shows promising results, the data from the R34 will be used to support a full-scale trial focused on improving routine healthcare practice and informing healthcare policy for the prevention or management of diabetes and obesity. Therefore, interventions must be integrated into the existing healthcare structure and/or processes. The healthcare setting may not be used solely as a venue for recruitment.

Funding Opportunity PAR-18-923 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement (FOA) is to support innovative studies to identify and understand the immunological responses that mediate protection from Mycobacterium tuberculosis (Mtb) infection or following vaccination with Bacillus Calmette-Gurin (BCG) or investigational vaccines. Studies may focus on any stage of mycobacterial infection and may include HIV-infected or uninfected individuals. Development of novel functional assays to assess host response and inclusion of immune profiling and systems biology approaches are encouraged. This FOA seeks to stimulate innovative research in deciphering immune mechanisms in humans required for protection from Mtb infection or tuberculosis (TB) disease, or induced by TB vaccines that go beyond what have traditionally been investigated in TB.

Funding Opportunity PAR-18-925 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity? Announcement (FOA) is to request research applications that test innovative approaches to improve diabetes and obesity prevention and/or treatment in healthcare settings where individuals receive their medical care?. Research applications should be designed to test practical and sustainable strategies to improve processes of care and health outcomes for individuals with or at risk of diabetes and/or obesity. The research should also focus on approaches with the potential to be broadly disseminated outside the specific setting where it is being tested. The goal of the research is to obtain results that will improve healthcare practice and inform healthcare policy for the prevention or management of these conditions. Therefore, interventions must be integrated into the existing healthcare structure and/or processes. The healthcare setting may not be used solely as a venue for recruitment.

Negotiable: Paramount Recruitment: Bioinformatician - Cancer Analysis 100,000 Genomes Project - Bioinformatics - Central London! Paramount are working in partnership with Genomics England to expand their team in order to deliver success with the 100,000 Genomes Project. London, England

Notice NOT-HS-18-016 from the NIH Guide for Grants and Contracts

Notice NOT-TR-18-032 from the NIH Guide for Grants and Contracts

Notice NOT-HD-18-019 from the NIH Guide for Grants and Contracts

Notice NOT-AR-19-009 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-085 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-077 from the NIH Guide for Grants and Contracts

Notice NOT-HD-18-016 from the NIH Guide for Grants and Contracts

Notice NOT-MD-18-016 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-DK-18-510 from the NIH Guide for Grants and Contracts. The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)s Symptoms of Lower Urinary Tract Dysfunction Research Network (LURN) conducts multi-site, multi-disciplinary studies of Lower Urinary Tract Dysfunction (LUTD) to better define clinical phenotype, to better describe the impact and diversity of symptoms, and to develop new patient-centric tools for improved measurement of clinical symptoms, all with the goals of informing future clinical studies and improving patient care. The purpose of this Limited Competition Funding Opportunity Announcement (FOA) is to invite applications from current LURN Research Sites for a second five-year Project Period.